To decipher if in recurrent tumors, either dormant glioblastoma cells regain proliferative capacity when reactive TCR-T cells are no longer present within the glioblastoma microenvironment54,55, or MHC and/or antigen loss occurrs56,57, we analyzed post-mortem tumors reaching preclinical termination criteria or experimental endpoint. The gene discussed is HLA-C; the disease is glioblastoma.